Consequently, extensive efforts have been made to develop AMPK-activating drugs for potential therapeutic use in treating metabolic diseases (type 2 diabetes, obesity, cardiovascular disease) and also cancer and inflammatory diseases. This evidence concerns the gene PRKAB1 and cancer.